Mora PJ, Ibáñez HL, Paredes PJC

Language: Spanish
References: 30
Page: 266-272
PDF size: 164.45 Kb.

ABSTRACT

Background: Polycystic ovarian syndrome (PCOS) is a risk factor for developing type 2 diabetes mellitus (T2D); hyperinsulinism episodes produce a relative risk (RR) of 1.8 of developing breast cancer. It hasn’t been described the association of T2D + PCOS and PCOS + breast cancer in Mexican patients.
Objectives: To determine if PCOS and PCOS + T2D are a factor associated with breast cancer.
Material and methods: We performed a case-control study of 29 patients with T2D + PCOS and breast cancer and 40 patients with breast cancer, in which 30 clinical variables were evaluated.
Results: We found an odds ratio (OR) of having a relative with T2D and breast cancer of 5.55 (95% CI 0.798-38.71), p of 0.123. It was identified an OR of having breast cancer and T2D of 2.857 (95% CI 0925-8823) with p of 0.068. Patients with PCOS and a firstline relative with breast cancer had an OR of 1.308 (95% CI 0645-2653), with a p of 0.518. There is an association between body mass index (BMI) and PCOS in patients with breast cancer with an OR of 3.6 (95% IC 1036-12507) and p of 0.044. The OR who have PCOS and DM2 for developing breast cancer is of 1.209 (95% CI 0533-2743), the OR of having PCOS and develop DM2 in patients with breast cancer is 0.775 (95% CI 0.259-2.3181).
Conclusions: PCOS and PCOS + T2D are potential risk factors for development of breast cancer in the Mexican population, although further studies are needed with larger samples to demonstrate this association.

REFERENCES

1. Kathleen AC. Hyperglycemia, obesity, and cancer risks on the Horizon. JAMA 2005;293-299.

2. Barone BB, Yeh HC, Snyder CF. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 2010;33:931-939.

3. Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet 2010;32:120-132.

4. Schott S. Breast cancer and diabetes mellitus. Exp Clin Endocrinol Diabetes 2010;118:673-677.

5. Sang MP. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 2006;24:5017-5024.

6. Bethany B. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus. A systematic review and meta-analysis. JAMA 2008;23:2754-2764.

7. Shichong L, Jinxin L, Wen W, Lijung W, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pacific J Cancer Prev 2011;12:2011-2034.

8. Kimberly SP, Bethany B, Claire F, Snyder S, et al. Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J Clin Oncol 2010;29:40-46.

9. Bosetti C, Rodriguez T, Chatenoud L, Bertuccio P, et al. Trends in cancer mortality in Mexico, 1981-2007. Eur J Cancer Prev 2011;20:355-363.

10. Robles CJ, Ruvalcaba LE, Maffuz A, Rodríguez CS. Cáncer de mama en mujeres mexicanas menores de 40 años. Ginecol Obstet Mex 2011;79:482-488.

11. Vargas CM, Gabriel SB, Herrera-PJ. Síndrome de ovarios poliquísticos: abordaje diagnóstico y terapéutico. Rev Biomed 2003;14:191-203.

12. William E, Hardiman E. Familial associations in women with polycystic ovary syndrome. Fertil Steril 2005;80:23-31.

13. Ottar L, Tanbo T. Polycystic syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy

14. 15-25 years after ovarian wedge resection. Gynecol Endocrinol 2007;23(12):704-709.

15. Gadducci A, Gargani A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: Is there a link? Gynecol Endocrinol 2005;20(4):200-208.

16. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocrine-Related Cancer 2011;18:125-147.

17. Romieu I, Lajous M. The role of obesity, physical activity and dietary factors the risk for breast cancer: Mexican experience. Salud Publica Mex 2009;51:172-180.

18. Hachana M, Trimeche S, Ziadi S. Prevalence and characteristics of the MMTV-like associated breast carcinomas in Tunisia. Cancer Lett 2008;271:222-230.

19. Gallagher JE, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 210;21:610-618.

20. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.

21. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999;51(3):34-41.

22. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-120.

23. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer, et al. Serum insulin-likegrowth factor-I and breast cancer. Int J Cancer 2000;88:828-832.

24. Kaaks R, Lundin E, Manjer J, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes Control 2002;13:307-316.

25. Evans JM, Donnelly LA, Emslie-Smith AM. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305.

26. Esteva J, Ensor GN, Hortobagyi MH, He X, et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER21 breast cancer. Ann Oncol 2011;2:201-222.

27. Higginbotham S, Zuo-Feng Z. Dietary glycemic load and breast cancer risk in the Women’s Health Study. Cancer Epidemiol Biomarkers Prev 2004;13:65-70.

28. Jaclyn LB, Sussie A, HenrikToft S, Lars P, Lash T. Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2010;20(1);101-111.

29. Ferrara A. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011;34:11-15.

30. Moran C, Tena G, Moran S, Ruiz P, et al. Prevalence of polycystic ovary syndrome and related disorders in Mexican women. Gynecol Obstet Invest 2010;69(4):274-280.